Multiple choices for HIV therapy with integrase strand transfer inhibitors

Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this n...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffi, Francois, Wainberg, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549750/
https://www.ncbi.nlm.nih.gov/pubmed/23253887
http://dx.doi.org/10.1186/1742-4690-9-110
_version_ 1782256461131284480
author Raffi, Francois
Wainberg, Mark A
author_facet Raffi, Francois
Wainberg, Mark A
author_sort Raffi, Francois
collection PubMed
description Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.
format Online
Article
Text
id pubmed-3549750
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35497502013-01-23 Multiple choices for HIV therapy with integrase strand transfer inhibitors Raffi, Francois Wainberg, Mark A Retrovirology Viewpoints Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens. BioMed Central 2012-12-19 /pmc/articles/PMC3549750/ /pubmed/23253887 http://dx.doi.org/10.1186/1742-4690-9-110 Text en Copyright ©2012 Raffi and Wainberg; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoints
Raffi, Francois
Wainberg, Mark A
Multiple choices for HIV therapy with integrase strand transfer inhibitors
title Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_full Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_fullStr Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_full_unstemmed Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_short Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_sort multiple choices for hiv therapy with integrase strand transfer inhibitors
topic Viewpoints
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549750/
https://www.ncbi.nlm.nih.gov/pubmed/23253887
http://dx.doi.org/10.1186/1742-4690-9-110
work_keys_str_mv AT raffifrancois multiplechoicesforhivtherapywithintegrasestrandtransferinhibitors
AT wainbergmarka multiplechoicesforhivtherapywithintegrasestrandtransferinhibitors

Ejemplares similares